ULTRAGENYX PHARMACEUTICAL INC. Cash and Restricted Cash
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Cash and Restricted Cash of $113.33 million as of 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-08-03
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $113.33M.
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $229.20M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $103.04M.
- 2017-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $93.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-06-30 | $113.33M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $229.20M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $103.04M 10-Q · filed 2018-08-03 |
| 2017-06-30 | $93.02M 10-Q · filed 2018-08-03 |
| 2017-03-31 | $161.77M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $164.61M 10-Q · filed 2018-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |